Tag : Binimetinib

Gastroenterology

Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study

Newsemia
Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study Source link...
Latest News

Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer

Newsemia
CASTRES, France–(BUSINESS WIRE)–Pierre Fabre today announced interim analysis results from the Phase 3 BEACON CRC trial evaluating the combination of encorafenib, a BRAF inhibitor, binimetinib,...
Latest News

Pierre Fabre recibe una opinión positiva por parte de CHMP para BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) en pacientes adultos con melanoma con mutación de BRAF avanzado

Newsemia
CASTRES, Francia–(BUSINESS WIRE)–Pierre Fabre anunció hoy que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) adoptó una opinión...
Latest News

Pierre Fabre reçoit un avis positif du CHMP pour le BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) pour les patients adultes atteints d'un mélanome à mutation BRAF au stade avancé

Newsemia
CASTRES, France–(BUSINESS WIRE)–Pierre Fabre a annoncé aujourd’hui que le Comité des médicaments à usage humain (CHMP) de l’Agence européenne des médicaments (EMA) avait adopté un...
Latest News

Pierre Fabre riceve un'opinione positiva dal CHMP su BRAFTOVI® (encorafenib) e MEKTOVI® (binimetinib) in associazione nel trattamento di pazienti adulti affetti da melanoma avanzato con mutazione BRAF

Newsemia
CASTRES, Francia–(BUSINESS WIRE)–Pierre Fabre ha annunciato oggi che il Comitato per i medicinali per uso umano (CHMP) dell’Agenzia europea dei medicinali (EMA) ha adottato un’opinione...
Latest News

Pierre Fabre erhält positive Stellungnahme des CHMP für BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) bei erwachsenen Patienten mit fortgeschrittenem BRAF-mutiertem Melanom

Newsemia
CASTRES, Frankreich–(BUSINESS WIRE)–Pierre Fabre gab heute bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP) der Europäischen Arzneimittel-Agentur (EMA) in...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy